Why 360biolabs?

360biolabs is Australia’s most comprehensive specialty laboratory service organization for therapeutic, vaccine and diagnostic development. We develop and conduct pharmacokinetic (PK) and pharmaco-dynamic (PD) assays across a wide variety of therapeutic areas and provide extensive support services 
such as laboratory manuals and biobanking to ensure the success of preclinical studies and clinical trials.

Our Expertise

360biolabs has the capability to support bioanalysis for new and established small molecules, peptides, proteins and large molecules. Our industry experienced chemistry and biology teams enjoy the challenges of developing, validating and conducting sensitive quantitative determinations from a variety of biological matrices as well as metabolite identification and other complex analytical requests. Our immunology experts offer comprehensive analytical support for complex biologics, extensive immune monitoring capabilities and the flexibility to development assays for new technologies.

Our classically trained virology team, particularly experienced in respiratory virus research, add to the breadth of 360biolabs capabilities. The virology team has a wealth of industry experience; our scientists have worked with most virus families known to science and supported many clinical trials and regulatory submissions. In the molecular age, it can be challenging to find a team with cell culture based virology expertise and when we combine our virology, immunology and molecular biology teams, 360biolabs can support any end point required for vaccine or antiviral discovery and development.

The team at 360biolabs are driven by quality and our customer-focused business is founded on consistently meeting client requirements and enhancing their success. Our quality systems drive our preclinical and clinical activities from custom research to full assay validation, compliant with ICH, FDA and EMA.

Our Expansion

Experiencing a substantial increase in the number of early phase clinical trials from 2020 onwards, 360biolabs has significantly expanded its facility located within the Alfred Research Alliance in Melbourne, one of Australia’s leading medical research and education precincts, while opening a new facility in Brisbane.

In Melbourne, the facility incorporated a new flow cytometry suite and expanded bioanalytical footprint, incorporating 10 LC-MS/MS instruments. As Australia’s most comprehensive specialty laboratory, 360biolabs focused on expanding its bioanalytical capacity to support the 30% increase in small molecule clinical trials. To provide a solution for the continued demand for metabolite profiling and identification, instrumentation including Q-TOF and additional high sensitivity triple quadrupole LC-MS/MS instruments were introduced, enhancing capacity plus capability.

Our lab in Brisbane puts us in the right place at the right time – receiving requests to process samples for downstream enzymatic or immunological assessments within hours of blood draw. Receiving samples within a very short time-frame from sites and Phase 1 units located in and around Brisbane ensures sample integrity is maintained at the highest level, which is our utmost priority.

Whether it’s small molecules, biologics or other innovative solutions to human health, 360biolabs continues to respond to global unmet medical needs by providing specialty laboratory services to enable future medicines.